AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palombo, J. D.
Right arrow Articles by Bistrian, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palombo, J. D.
Right arrow Articles by Bistrian, B. R.
Agricola
Right arrow Articles by Palombo, J. D.
Right arrow Articles by Bistrian, B. R.

American Journal of Clinical Nutrition, Vol 50, 504-507, Copyright © 1989 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Blood carnitine status after orthotopic liver transplantation in patients with end-stage liver disease

JD Palombo, PR Borum, RL Jenkins, C Trey and BR Bistrian
Laboratory of Nutrition/Infection, New England Deaconess Hospital/Harvard Medical School, Boston, MA 02215.

We determined the effects of orthotopic liver transplantation on plasma and red cell carnitine concentrations in patients with end-stage liver disease. Before transplantation, plasma and red cell carnitine were significantly elevated above normal. The partitioning factor (ratio of red cell carnitine to plasma carnitine) was four times greater than that observed in our reference population. After hepatic replacement, plasma and red cell carnitine approached normal levels within 6 mo. The partitioning factor, however, remained elevated at that time. These results indicate that 1) there is no evidence for carnitine deficiency in severe liver disease on the basis of carnitine concentrations in the plasma and red compartments and 2) altered partitioning of carnitine between plasma and red cells persists for greater than or equal to 6 mo after hepatic replacement.


This article has been cited by other articles:


Home page
 J Child NeurolHome page
A. Nissenkom, S. H. Korman, O. Vardi, A. Levine, Z. Katzir, A. Ballin, and T. Lerman-Sagie
Carnitine-Deficient Myopathy as a Presentation of Tyrosinemia Type I
J Child Neurol, September 1, 2001; 16(9): 642 - 644.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by The American Society for Nutrition